Clinical effectiveness of decitabine in severe sickle cell disease

British Journal of Haematology

Volumn 141, Issue 1, 2008, Pages 126-129

  Saunthararajah, Yogen ^a,b   Molokie, Robert ^a   Saraf, Santosh ^a   Sidhwani, Seema ^a   Gowhari, Michel ^a   Vara, Steven ^a   Lavelle, Donald ^a   DeSimone, Joseph ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Differentiation therapy; Erythroid cell differentiation; Fetal haemoglobin; Haemoglobinopathies; Sickle

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ERYTHROPOIETIN; HYDROXYUREA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

DISEASE COURSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; HEALTH STATUS; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; OFF LABEL DRUG USE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANEMIA, SICKLE CELL; AZACITIDINE; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 40449130473     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07027.x     Document Type: Letter

References (8)

1. Chabot, G.G. Momparler, R.L. (1986) Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leukemia Research, 10, 533 537.
2. DeSimone, J., Koshy, M., Dorn, L., Lavelle, D., Bressler, L., Molokie, R. Talischy, N. (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood, 99, 3905 3908.
3. Koshy, M., Dorn, L., Bressler, L., Molokie, R., Lavelle, D., Talischy, N., Hoffman, R., van Overveld, W. DeSimone, J. (2000) 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood, 96, 2379 2384.
4. Koury, M.J. Bondurant, M.C. (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science, 248, 378 381.
5. Milhem, M., Mahmud, N., Lavelle, D., Araki, H., DeSimone, J., Saunthararajah, Y. Hoffman, R. (2004) Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood, 103, 4102 4110.
6. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. Carbone, P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649 655.
7. Saunthararajah, Y., Hillery, C.A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.H., Hoffman, R. DeSimone, J. (2003) Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood, 102, 3865 3870.
8. Visvader, J. Adams, J.M. (1993) Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood, 82, 1493 1501.